ArticleEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin2017
Analysis of OXA-204 carbapenemase-producing
Article in Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 2 syntheses or guidelines pooled it, 25 citations in OpenAlex.
- Gastrointestinal Endoscopy-Associated Infections: Update on an Emerging Issue.Digestive diseases and sciences · 2022Pooled it
- Burden of carbapenem non-susceptible infections in high-risk patients: systematic literature review and meta-analysis.Antimicrobial resistance and infection control · 2020Pooled it
- Genomic characterization of an ESBL-producingMicrobiology spectrum · 2026Article
- OXA-204 Carbapenemase in Clinical Isolate of Pseudomonas guariconensis, Tunisia.Emerging infectious diseases · 2025Article
- OXA-48-like carbapenemases inEmerging microbes & infections · 2024Article
- Article
- OXA-48-Like β-Lactamases: Global Epidemiology, Treatment Options, and Development Pipeline.Antimicrobial agents and chemotherapy · 2022Review
- Epidemiology and clinical characteristics of infection/colonization due to carbapenemase-producing Enterobacterales in neonatal patients.BMC microbiology · 2022Article
- A narrative review on current duodenoscope reprocessing techniques and novel developments.Antimicrobial resistance and infection control · 2021Review
- Clonal CTX-M-15-ProducingFrontiers in microbiology · 2021Article
- Emerging Antimicrobial-Resistant High-Risk Klebsiella pneumoniae Clones ST307 and ST147.Antimicrobial agents and chemotherapy · 2020Review
- The Global Ascendency of OXA-48-Type Carbapenemases.Clinical microbiology reviews · 2019Review
- Top-ten papers in Infection Control (2015-2017).Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2018Review
- Diversity of Carbapenemase-Producing Escherichia coli Isolates in France in 2012-2013.Antimicrobial agents and chemotherapy · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 7 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
OXA-48-like beta-lactamase producing bacteria are now endemic in several European and Mediterranean countries. Among this carbapenemase family, the OXA-48 and OXA-181 variants predominate, whereas other variants such as OXA-204 are rarely reported. Here, we report the molecular epidemiology of a collection of OXA-204-positive enterobacterial isolates (n = 29) recovered in France between October 2012 and May 2014. This study describes the first outbreak of OXA-204-producing
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.